BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics
Shots:
- BigHat Biosciences and Eli Lilly entered into a strategic collaboration to design and develop next-generation therapeutic antibodies using BigHat’s ML-powered Milliner platform and synthetic biology wet lab
- The collaboration includes up to two antibody programs and support for BigHat’s internal pipeline, including a next-gen ADC for GI cancers entering the clinic in 2026, with BigHat retaining full global rights
- Lilly will also make an equity investment in BigHat as part of its Lilly Catalyze360 providing funding for lab space, and drug development resources
Ref: BigHat Biosciences | Image: BigHat Biosciences & Eli Lilly
Related News:- Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
